Paracervical Block in Laparoscopic Hysterectomy (PALAPA)
Primary Purpose
Uterine Fibroid, Adenomyosis
Status
Unknown status
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Paracervical block
5% bupivacaine
Normal saline
Sponsored by
About this trial
This is an interventional treatment trial for Uterine Fibroid
Eligibility Criteria
Inclusion Criteria:
- age between 18 and 65 years
- American Society of Anesthesiologists physical status (ASAPS) classification I-II
- the absence of pregnancy at the time of surgery
Exclusion Criteria:
- history of cervical surgery such as conization or cerclage
- inability to perform the paracervical block due to anatomical abnormalities (i.e., very atrophic or small cervix)
- allergy to bupivacaine, planned concomitant surgical procedures involving extensive additional tissue manipulation such as pelvic lymph node dissection
- any concomitant surgery of pelvic floor repair (uterosacral ligament suspension or sacrocolpopexy) or vaginal procedures (anterior or posterior colporrhaphy or mid-urethral slings), previously taking opioids for chronic pain
- inability to accurately express their pain
Sites / Locations
- Samsung Medical Center
- Kangbuk Samsung HospitalRecruiting
- Wonju Severance Christian HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Paracervical block with 5% bupivacaine
Paracervical block with normal saline
Arm Description
The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Outcomes
Primary Outcome Measures
Postoperative pain
The scale was presented as a 10-cm line with verbal descriptors ranging from "no pain" to "worst imaginable pain".
Secondary Outcome Measures
Frequency of pills/injections requested
Narcotic and non-narcotic use were measured by number of pills/injections requested within 24-hour after surgery.
Full Information
NCT ID
NCT03792009
First Posted
December 28, 2018
Last Updated
February 21, 2019
Sponsor
Kangbuk Samsung Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03792009
Brief Title
Paracervical Block in Laparoscopic Hysterectomy
Acronym
PALAPA
Official Title
A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Paracervical Block Before Total Laparoscopic Hysterectomy for Postoperative Pain Control (PALAPA):
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
February 21, 2019 (Actual)
Primary Completion Date
February 1, 2021 (Anticipated)
Study Completion Date
February 1, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kangbuk Samsung Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
It remains controversial whether paracervical block should be performed as a powerful strategy for pain relief in total laparoscopic hysterectomy (TLH), because convincing conclusions are difficult to draw because of the heterogeneous and contradictory nature of the literature. Therefore, the aim of this study was to evaluate the efficacy of paracervical blocks using with 0.5% bupivacaine prior to TLHs for benign gynecologic conditions on postoperative pain relief.
Detailed Description
Postoperative pain management is an important component of patient care and satisfaction after surgery. Although contemporary changes such as a shift to minimally invasive approaches and an introduction of the enhanced recovery after surgery (ERAS) program have resulted in improved outcomes, a large number of patients undergoing surgery have still inadequate pain control. Paracervical block is a single-injection of anesthetic around the cervix at a depth of about 1 cm, diffusing anesthetic into the second to fourth sacral nerve roots passing through Frankenhäuser plexus. Moreover, recent randomized trials demonstrated that patients who underwent vaginal hysterectomy and received a paracervical block had lower postoperative pain in the first 3-6 hours compared with placebo.
However, it remains controversial whether paracervical block should be performed as a powerful strategy for pain relief in total laparoscopic hysterectomy (TLH), because convincing conclusions are difficult to draw because of the heterogeneous and contradictory nature of the literature. Therefore, the aim of this study was to evaluate the efficacy of paracervical blocks using with 0.5% bupivacaine prior to TLHs for benign gynecologic conditions on postoperative pain relief.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uterine Fibroid, Adenomyosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
86 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Paracervical block with 5% bupivacaine
Arm Type
Experimental
Arm Description
The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Arm Title
Paracervical block with normal saline
Arm Type
Placebo Comparator
Arm Description
The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Intervention Type
Device
Intervention Name(s)
Paracervical block
Other Intervention Name(s)
Experimental arm, Control arm
Intervention Description
The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Intervention Type
Drug
Intervention Name(s)
5% bupivacaine
Other Intervention Name(s)
Experimental arm
Intervention Description
The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Intervention Type
Drug
Intervention Name(s)
Normal saline
Other Intervention Name(s)
Control arm
Intervention Description
The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Primary Outcome Measure Information:
Title
Postoperative pain
Description
The scale was presented as a 10-cm line with verbal descriptors ranging from "no pain" to "worst imaginable pain".
Time Frame
at 6-hour after surgery
Secondary Outcome Measure Information:
Title
Frequency of pills/injections requested
Description
Narcotic and non-narcotic use were measured by number of pills/injections requested within 24-hour after surgery.
Time Frame
Within 24-hour after surgery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age between 18 and 65 years
American Society of Anesthesiologists physical status (ASAPS) classification I-II
the absence of pregnancy at the time of surgery
Exclusion Criteria:
history of cervical surgery such as conization or cerclage
inability to perform the paracervical block due to anatomical abnormalities (i.e., very atrophic or small cervix)
allergy to bupivacaine, planned concomitant surgical procedures involving extensive additional tissue manipulation such as pelvic lymph node dissection
any concomitant surgery of pelvic floor repair (uterosacral ligament suspension or sacrocolpopexy) or vaginal procedures (anterior or posterior colporrhaphy or mid-urethral slings), previously taking opioids for chronic pain
inability to accurately express their pain
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Taejong Song, M.D., Ph.D.
Phone
+821040358405
Email
taejong.song@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Su Yaen Kim, M.D.
Phone
+82220012036
Email
suyeon0819.kim@samsung.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Taejong Song, M.D., Ph.D.
Organizational Affiliation
Kangbuk Samsung Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
03181
Country
Korea, Republic of
Individual Site Status
Suspended
Facility Name
Kangbuk Samsung Hospital
City
Seoul
ZIP/Postal Code
110-746
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Taejong Song, MD PhD
Phone
82-2-2001-2582
Email
taejong.song@gmail.com
First Name & Middle Initial & Last Name & Degree
Taejong Song, MD, PhD
Facility Name
Wonju Severance Christian Hospital
City
Wonju
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
San-Hui Lee, M.D.
Phone
+821040358405
Email
saniarami@gmail.com
First Name & Middle Initial & Last Name & Degree
San-Hui Lee, M.D.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Paracervical Block in Laparoscopic Hysterectomy
We'll reach out to this number within 24 hrs